Navigation Links
Medivation Announces Upcoming Presentation of New MDV3100 Data in Patients With Advanced Prostate Cancer at 45th American Society of Clinical Oncology Annual Meeting
Date:5/21/2009

SAN FRANCISCO, May 21 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that additional clinical results from a Phase 1-2 clinical trial involving 140 men with advanced prostate cancer evaluating MDV3100, a next-generation androgen receptor antagonist, will be presented in an oral session at the American Society of Clinical Oncology (ASCO) Annual Meeting in Orlando, Fla.

    Oral Abstract Session:      Genitourinary (Prostate) Cancer

    Abstract Title:            "Antitumor Activity of MDV3100 in a Phase 1-2
                               Study of Castration-Resistant Prostate Cancer
                               (CRPC)" (Abstract #5011)

    Presentation Date/Time:     Saturday, May 30, at 4:15 p.m. ET

    Presenter:                  Dr. Howard Scher, principal investigator,
                                chief of the Genitourinary Oncology Service
                                and the D. Wayne Calloway Chair in Urologic
                                Oncology at Memorial Sloan-Kettering Cancer
                                Center in New York

    Location:                   Level 3, Chapin Theater W320

Additionally, this abstract was selected by ASCO for inclusion in the Best of ASCO(R) program, an educational initiative covering highlights from the ASCO Annual Meeting to increase global access to cutting-edge science.

Medivation recently received written permission from the U.S. Food and Drug Administration to begin a pivotal Phase 3 trial of MDV3100 in patients with advanced prostate cancer. The primary endpoint of the trial will be overall survival.

About Prostate Cancer

Prostate cancer is the most common non-skin cancer in the United States and the third most common cancer worldwide. More than 1 million men in the U
'/>"/>

SOURCE Medivation, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Medivation to Announce Early Positive Data from Phase 1-2 Hormone Refractory Prostate Cancer Trial and Host Conference Call and Webcast on Monday, November 5, 2007
2. Medivation Plans to Initiate Pivotal Confirmatory Phase 3 Trial of Dimebon(TM) for Alzheimers Disease in Second Quarter of 2008
3. Medivation to Present at Cowen and Companys 28th Annual Health Care Conference
4. Medivation Announces Participation in Upcoming Conferences
5. Medivation Announces Participation in 27th Annual J.P. Morgan Healthcare Conference
6. Medivation Announces Participation in Upcoming Conferences
7. Medivation to Host Conference Call and Slide Presentation at 4:30 p.m. EST Wednesday, February 25, to Discuss New MDV3100 Efficacy and Safety Data From Trial in Castration-Resistant Prostate Cancer Patients
8. Medivation Announces Fourth Quarter and Year-End 2008 Teleconference and Webcast on March 16, 2009
9. Medivation Receives FDA Permission to Initiate Phase 3 Trial of MDV3100 in Castration-Resistant Prostate Cancer
10. Medivation Reports First Quarter 2009 Financial Results and Provides Corporate Update
11. Medivation to Present at the Leerink Swann Novel Cancer Therapeutics Roundtable Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... In today's healthcare landscape, where costs ... be challenging for doctors and hospitals to keep up ... , Austin-based HealthTronics, Inc. is offering a ... therapies for clinically sophisticated applications. The company has now ... Laser Ventures, Inc ., a mobile laser technology ...
(Date:5/27/2015)... 27, 2015 Dr. Omar Ibrahimi, Dermatologist ... Stamford, CT has been selected as part of a ... nationwide (and the only physician in Connecticut) to offer ... for the removal of submental fat (double chin). The ... time, no surgery and minimal risks. Dr. Ibrahimi is ...
(Date:5/27/2015)... NOVAtime Technology, Inc. ( http://www.novatime.com ), a leading ... announced today that SanMar Corporation successfully implemented the ... and point tracking processes for over 3,000 employees ... , Family-owned since 1971, Seattle-based SanMar Corporation is ... and mill brands. SanMar supplies apparel and accessories ...
(Date:5/27/2015)... In support of a new ... the Journal of American Geriatrics Society about the link ... Bedford Commons OB-GYN P.A . is reiterating the nutritional ... , To examine the relationship between diet soda ... Longitudinal Study of Aging (SALSA) tracked the soda consumption ...
(Date:5/27/2015)... AR (PRWEB) May 27, 2015 ... today announce a partnership to provide CMSA's Career ... community. This collaboration seeks to strengthen the case/care ... through CMSA’s CKP program. The mutually beneficial agreement ... identifying individual skills of talent in the healthcare, ...
Breaking Medicine News(10 mins):Health News:HealthTronics Invests in Additional Mobile Medical Technologies As Cost Efficient Solution for Hospitals, Doctors 2Health News:HealthTronics Invests in Additional Mobile Medical Technologies As Cost Efficient Solution for Hospitals, Doctors 3Health News:Connecticut Skin Institute First in Connecticut to Offer New Surgery-Free “Double Chin” Fat Reduction Treatment 2Health News:Connecticut Skin Institute First in Connecticut to Offer New Surgery-Free “Double Chin” Fat Reduction Treatment 3Health News:SanMar Corporation Successfully Implemented NOVAtime Workforce Management Solution across 9 locations 2Health News:SanMar Corporation Successfully Implemented NOVAtime Workforce Management Solution across 9 locations 3Health News:Recent Study About the Link Between Diet Sodas and Abdominal Fat Reinforces Bedford Commons OB-GYN's Recommendation to Drink Plenty of Water 2Health News:Case Management Society of America Partners with Medix to Offer Career and Knowledge Pathways 2Health News:Case Management Society of America Partners with Medix to Offer Career and Knowledge Pathways 3
... , ... Pain Relief Cream unique in the topical analgesic market. , ... Decatur, AL (PRWEB) March 8, 2010 -- Physician,s Pain Relief ... agent. Studies show HEPES Ester effectively relieved arthritis and myositis pain by reducing redness and ...
... The 2010 Sleep in America poll released today ... in the sleep habits and attitudes of Asians, Blacks/African-Americans, ... examine sleep among these four ethnic groups. NSF,s ... of respondents from each ethnic group agree that poor ...
... at the Stanford University School of Medicine have devised a ... virtually separate a whole-blood sample into its different cell types ... of those cell types. In a study to be ... scientists reported that they had successfully used the new technique ...
... ... and sleep disorders will receive international recognition at the American College of Physicians (ACP) ... ... Elizabeth Internal Medicine residents in hypertension therapy and sleep disorders will receive international recognition ...
... ... Cinco de Mayo Half Marathon and the 12th Annual “Reaching for the Cure” 10K Run, ... ... (PCRF) announced the official sponsors for the annual “Reaching for the Cure” Half Marathon ...
... ... we could reduce number of patients undergoing leg amputation and detect heart ... or blockage of arteries in the legs) were given higher priority by ... amputations are carried out in England and Wales, the majority of which ...
Cached Medicine News:Health News:Physician's Pain Relief Cream Includes Patented Anti-inflammatory in New Formula 2Health News:Physician's Pain Relief Cream Includes Patented Anti-inflammatory in New Formula 3Health News:Poll reveals sleep differences among ethnic groups 2Health News:Poll reveals sleep differences among ethnic groups 3Health News:Poll reveals sleep differences among ethnic groups 4Health News:Poll reveals sleep differences among ethnic groups 5Health News:Poll reveals sleep differences among ethnic groups 6Health News:Mathematical innovation turns blood draw into information gold mine in Stanford study 2Health News:Mathematical innovation turns blood draw into information gold mine in Stanford study 3Health News:Mathematical innovation turns blood draw into information gold mine in Stanford study 4Health News:St. Elizabeth Medical Residents to Present Research at International Meeting, 2Health News:Sponsors for the 2010 Pediatric Cancer Research Foundation “Reaching for the Cure” Annual Cinco de Mayo Run/Walk Fundraising Event 2Health News:Sponsors for the 2010 Pediatric Cancer Research Foundation “Reaching for the Cure” Annual Cinco de Mayo Run/Walk Fundraising Event 3Health News:Arterial disease awareness cuts heart attacks and leg amputations, claim UK vascular surgeons 2Health News:Arterial disease awareness cuts heart attacks and leg amputations, claim UK vascular surgeons 3
(Date:5/27/2015)...  Actavis plc (NYSE: ACT ) announced ... Food and Drug Administration (FDA) as a twice-daily, ... syndrome with diarrhea (IBS-D). VIBERZI (eluxadoline) has mixed ... agonist, a delta receptor antagonist, and a kappa ... "The FDA,s approval of VIBERZI ...
(Date:5/27/2015)... May 27, 2015   Madison Laser Tattoo Removal ... Madison and the surrounding area to offer ... Madison Laser Tattoo Removal is dedicated to bringing a solution ... Wisconsin . "I founded Madison Laser Tattoo ... and return their skin to its natural look," said ...
(Date:5/27/2015)...  Sequenom, Inc. (NASDAQ: SQNM ), a life ... development of innovative products and services, today announced that ... laboratory operations in Grand Rapids, Michigan ... , North Carolina.  Sequenom Laboratories, cystic fibrosis carrier ... North Carolina laboratory location.  ...
Breaking Medicine Technology:Actavis Receives FDA Approval for VIBERZI (eluxadoline) for the Treatment of Irritable Bowel Syndrome with Diarrhea (IBS-D) in Adults 2Actavis Receives FDA Approval for VIBERZI (eluxadoline) for the Treatment of Irritable Bowel Syndrome with Diarrhea (IBS-D) in Adults 3Actavis Receives FDA Approval for VIBERZI (eluxadoline) for the Treatment of Irritable Bowel Syndrome with Diarrhea (IBS-D) in Adults 4Actavis Receives FDA Approval for VIBERZI (eluxadoline) for the Treatment of Irritable Bowel Syndrome with Diarrhea (IBS-D) in Adults 5Madison Laser Tattoo Removal Brings Superior Laser Tattoo Removal Services To Madison, WI With Astanza Duality 2Sequenom Laboratories To Consolidate Michigan And North Carolina Facilities 2Sequenom Laboratories To Consolidate Michigan And North Carolina Facilities 3
Tip is bent towards port for downward irrigation. 25G x 5/8in (.50 x 22mm)...
... product designed for LASIK surgery and ... to irrigate the corneal interface and/or ... insertion under the flap and helps ... provide multi-directional irrigation.27G x 7/8in (.40 ...
... designed for LASIK surgery and other types ... corneal interface and/or stromal bed. Flattened tip ... helps elevate the flap edge. Multiple ports ... x 22mm) Formed 7mm from end. Two ...
... Unique product designed for LASIK ... surgery. Designed to irrigate the corneal ... provides easy insertion under the flap ... Multiple ports provide multi-directional irrigation. 21G ...
Medicine Products: